JAK 阻害薬と悪性腫瘍リスク: さまざまな疾患のメタ解析
Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.
June 2023
バリシチニブは関節リウマチ患者の骨量と力学機能を改善 – 前向き介入BARE BONE 治験結果
Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print
The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.
Keywords:
炎症性疾患男性患者の精子と性ホルモンに対するフィルゴチニブの影響: フェーズ2, 無作為化, 二重盲検, プラセボ対照 マンタおよびマンタレイ試験
Ann Rheum Dis 2023;82:1049–1058
Reinisch, et al. show that filgotinib treatment has no effect on semen parameters for men with active inflammatory diseases. This contrasts with pre-clinical studies that showed fertility issues in male animals.
Keywords:
May 2023
細胞を標的とした生物学的製剤またはJAK阻害薬で治療中の関節リウマチ患者におけるアジュバント添加リコンビナント帯状疱疹ワクチンの免疫原性と安全性: 前向き観察研究
Int JMol Sci 2023;24(8):6967 doi 10.3390/ijms24086967
A prospective observational study showed that recombinant zoster vaccine (RZV) immunogenicity is not impaired in RA patients on JAK inhibitors or anti-cellular bDMARDs.
Keywords:
活動性乾癬性関節炎患者におけるウパダシチニブの有効性と安全性: ２つのフェーズ３試験結果
Arthritis Res Ther. 2023;25(1):56 doi 10.1186/s13075-023-03027-5
Evidence from two phase 3 RCTs showed that patients with PsA and axial involvement had greater responses when treated with a once-daily oral dose of 15 mg upadacitinib versus placebo, and a similar or greater response versus adalimumab. Safety results were comparable between patients with or without axial involvement.
Keywords:
April 2023
2つの異なるトファシチニブ治療グループのTNF阻害薬に対する相対リスク: オープンラベル無作為化試験のORAL Surveillance
Ann Rheum Dis. 2023;82(7):901-910 doi: 10.1136/ard-2022-223715
Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.
Keywords:
生物学的または分子標的抗リウマチ薬治療中の 関節リウマチ患者の間質性肺疾患の罹患率
JAMA Netw Open. 2023;6(3):e233640 doi: 10.1001/jamanetworkopen.2023.3640
Retrospective cohort study results suggest that treatment with tofacitinib, and perhaps other JAK inhibitors, may provide a benefit in reducing the risk of developing RA-Interstitial Lung Disease (ILD).
Keywords:
乾癬性関節炎患者におけるトファシチニブ治療の有効性、安全性、継続率の性差: フェーズ3および長期延長試験の事後解析
RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718
Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.
Keywords:
March 2023
乾癬性関節炎と乾癬でトファシチニブ治療中の患者におけるベースライン心血管疾患リスクと主要心血管有害事象と悪性腫瘍罹患率の関連
Ther Adv Musculoskelet Dis. 2023 doi: 10.1177/1759720X221149965
Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.
Keywords:
関節リウマチ、乾癬性関節炎、強直性脊椎炎を対象とした１５０００人年におよぶウパダシチニブの安全性
RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735
Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.